中山大学肿瘤防治中心近日发布消息，该中心教授孙颖、马骏、吕佳蔚团队在国际顶级肿瘤期刊《癌细胞》上在线发表了一项关于鼻咽癌治疗效果监测的最新研究成果。该研究发现，一种名为EBV DNA的生物标志物可以实时监测鼻咽癌患者的治疗效果，为个体化治疗提供了可靠的生物标志物。
EBV即EB病毒，是鼻咽癌的主要致病因素之一，华南地区是鼻咽癌的高发地区。研究团队通过跟踪1000例接受治疗的鼻咽癌患者，完整绘制了治疗过程中EBV DNA的动态图谱。研究发现，患者的病毒DNA在治疗初期会逐渐减少，但随着治疗的进行，减少的速度会放慢，尤其是在治疗的第三阶段，只有很少的患者血液中的病毒DNA能够完全消失。
研究团队还发现，如果患者的病毒DNA在治疗中迅速消失，他们的肿瘤也会快速缩小，治疗效果就会很好。相反，如果病毒DNA持续增加，患者的肿瘤可能会继续增大，治疗效果就会变差。这表明检测患者血液中的这种病毒DNA可以知道患者的病情如何，以及治疗效果好不好。
这项研究不仅为鼻咽癌的治疗提供了新的生物标志物，还提出了可利用治疗中病毒DNA动态清零情况来帮助患者定制基于实时复发风险的个体化治疗策略。孙颖教授介绍，研究者基于这项研究，提出了可利用治疗中病毒DNA动态清零情况来帮助患者定制基于实时复发风险的个体化治疗策略，而非现有的“一成不变”的治疗模式。该院正牵头推进检测的标准化，推动这一新成果在全国更多医疗机构落地。
这一研究成果为鼻咽癌患者的个体化治疗提供了新的希望，有望提高治疗效果，降低复发风险，为患者带来更好的治疗体验。
英语如下：
Title: “Guangdong Team Innovates in Monitoring Efficacy of Nasopharyngeal Cancer Treatment”
Keywords: Liquid Biopsy, Nasopharyngeal Cancer, Personalized Treatment
News Content:
The Cancer Institute of Sun Yat-sen University recently released a statement, announcing that a team led by professors Sun Ying, Ma Jun, and Lv Jiayu from the center has published a new research achievement on monitoring the efficacy of nasopharyngeal cancer (NPC) treatment in the international top cancer journal “Cancer Cell.” The study found that a biomarker known as EBV DNA can be used to monitor the treatment efficacy of NPC patients in real-time, providing a reliable biomarker for personalized treatment.
EBV stands for Epstein-Barr virus, one of the major causes of nasopharyngeal cancer, and the South China region is a high incidence area for the disease. The research team tracked 1000 NPC patients undergoing treatment and comprehensively mapped the dynamic profile of EBV DNA during the treatment process. The study found that the viral DNA in patients decreases gradually at the beginning of treatment, but the rate of decrease slows down as the treatment progresses, especially in the third phase of treatment, where only a few patients see their viral DNA completely disappear from their blood.
The research team also discovered that if the viral DNA in patients rapidly diminishes during treatment, their tumors will shrink quickly, leading to good treatment outcomes. Conversely, if the viral DNA continues to increase, the tumors may continue to grow, resulting in poor treatment outcomes. This indicates that detecting this viral DNA in patients’ blood can tell how their condition is and whether the treatment is effective.
This study not only provides a new biomarker for the treatment of nasopharyngeal cancer but also proposes the possibility of utilizing the dynamic elimination of viral DNA during treatment to help patients customize individualized treatment strategies based on real-time risk of recurrence. Professor Sun Ying explained that based on this study, researchers have proposed a strategy to customize individualized treatment strategies based on the dynamic elimination of viral DNA during treatment, rather than the current “one-size-fits-all” approach. The hospital is leading the way in promoting the standardization of the test and pushing this new achievement to be implemented in more medical institutions nationwide.
This research result offers new hope for the personalized treatment of NPC patients, with the potential to improve treatment efficacy and reduce the risk of recurrence, bringing patients a better treatment experience.
【来源】http://www.chinanews.com/sh/2024/07-26/10258242.shtml
Views: 2